[1] Zabaleta N, Hommel M, Salas D, et al. Genetic-based approaches to inherited metabolic liver diseases[J]. Hum Gene Ther, 2019,30(10):1190-1203.
[2] Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A[J]. N Engl J Med, 2023,388(8):694-705.
[3] Miesbach W, Peyvandi F, Pierce G F. AAV gene therapy in severe hemophilia B[J]. N Engl J Med, 2025,393(8):829-830.
[4] Hu T, Chitnis N, Monos D, et al. Next-generation sequencing technologies: an overview[J]. Hum Immunol, 2021,82(11):801-811.
[5] Brouwers M C G J, Cassiman D. Rare monogenic causes of steatotic liver disease masquerading as MASLD[J]. J Hepatol, 2024,80(6):e252-e253.
[6] Liebe R, Esposito I, Bock H H, et al. Diagnosis and management of secondary causes of steatohepatitis[J]. J Hepatol, 2021,74(6):1455-1471.
[7] Rajan R, Chapla A, Johnson J, et al. A series of genetically confirmed congenital lipodystrophy and diabetes in adult southern Indian patients[J]. Sci Rep, 2024,14(1):28277.
[8] Vilarinho S, Ajmera V, Zheng M, et al. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD[J]. Hepatology, 2021,74(4):2241-2250.
[9] Panzer M, Viveiros A, Schaefer B, et al. Synonymous mutation in adenosine triphosphatase copper-transporting beta causes enhanced exon skipping in Wilson disease[J]. Hepatol Commun, 2022,6(7):1611-1619.
[10] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015,17(5):405-424.
[11] Sookoian S, Pirola C J, Valenti L, et al. Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology[J]. Hepatology, 2020,72(1):330-346.
[12] Khera A V, Chaffin M, Aragam K G, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations[J]. Nat Genet, 2018,50(9):1219-1224.
[13] Ow J R, Imagawa E, Chen F, et al. Developing splice-switching oligonucleotides for urea cycle disorder using an integrated diagnostic and therapeutic platform[J]. J Hepatol, 2025,83(2):411-425.
[14] Lacabanne D, Sowton A P, Jose B, et al. Current understanding of pathogenic mechanisms and disease models of citrin deficiency[J]. J Inherit Metab Dis, 2025,48(2):e70021.
[15] Nathwani A C, McIntosh J, Sheridan R. Liver gene therapy[J]. Hum Gene Ther, 2022,33(17-18):879-888.
[16] Kozlov D S, Rodimova S, Filatov P, et al. Genomic medicine in hepatology: mechanisms and liver treatment strategies[J]. Mol Med, 2025,31(1):302.
[17] Lauffer M C, van Roon-Mom W, Aartsma-Rus A. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders[J]. Commun Med (Lond), 2024,4(1):6.
[18] Bergmark B A, Marston N A, Prohaska T A, et al. Targeting APOC3 with olezarsen in moderate hypertriglyceridemia[J]. N Engl J Med, 2025,393(13):1279-1291.
[19] Fancello L, Manconi M, Manca M L. An overview of strategies and challenges adopted to silence BCR-ABL gene by small interfering RNA[J]. Nanomedicine (Lond), 2025:1-20.
[20] Enakhumhe J, Sheikh Y. Casgevy gene therapy could be life changing for people with sickle cell disease[J]. BMJ, 2025,389:r840. |
